Combined esterified estrogen and methyltestosterone treatment for dry eye syndrome in postmenopausal women.
OBJECTIVE
To determine whether systemic replacement with combined esterified estrogen (EE) and methyltestosterone (MT) (EE + MT) would reduce symptoms and promote clinical improvement in postmenopausal women with dry eye syndrome (DES).


METHODS
Retrospective, noncomparative, interventional case series.


METHODS
Investigators reviewed the charts of 11 postmenopausal women treated within the last 3 years with EE + MT.


RESULTS
The mean patient age was 65.2 years (standard deviation [SD] 11.4, range 48-84 years). The mean treatment duration was 12.2 months (SD 6.2 months, range 4-24 months). Ten (91%) of 11 patients reported improvement in dry eye symptoms while receiving treatment. For these 10, relief occurred after an average of 4.1 months of treatment (SD 3.2, range, 1-9 months).


CONCLUSIONS
Treatment with EE + MT may be efficacious for DES of various etiologies. A randomized placebo-controlled trial is planned to further evaluate these encouraging findings.
Scott
Garrett
G
Ocular Surface Center, Doheny Eye Institute, 1450 San Pablo Street DE15704, Los Angeles, CA 90033, USA.
Yiu
Samuel C
SC
Wasilewski
Daniel
D
Song
Jonathan
J
Smith
Ronald E
RE
D000368:Aged; D000369:Aged, 80 and over; D004338:Drug Combinations; D015352:Dry Eye Syndromes / Q000188:drug therapy*; D004967:Estrogens / Q000627:therapeutic use*; D042724:Estrogens, Esterified (USP); D005260:Female; D006801:Humans; D008777:Methyltestosterone / Q000627:therapeutic use*; D008875:Middle Aged; D017698:Postmenopause; D012189:Retrospective Studies; D016896:Treatment Outcome
D004338:Drug Combinations; C084327:Estratest-HS; D004967:Estrogens; D042724:Estrogens, Esterified (USP); D008777:Methyltestosterone